Ligand Pharmaceuticals Incorporated has grown revenue 17% a year over three years and 4.1% a year over five, with earnings per share compounding at 80%. Revenue growth, 3-year annual rate: +17% (Biotechnology median +21%). Revenue growth, 5-year rate: +4.1%, growth has picked up over the last three years. Earnings per share, 3-year rate: +80%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

LGNDLigand Pharmaceuticals Incorporated

HealthcareUSD

$287.86

$147.0152 weeks$316.44

Is it growing?

Is LGND growing?

Ligand Pharmaceuticals Incorporated has grown revenue 17% a year over three years and 4.1% a year over five, with earnings per share compounding at 80%.

+17%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +4.1%
Revenue growth, 5-year rate · +17% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +80%
Earnings per share, 3-year rate · revenue +17% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed